Development of new vaccine for treating lung ca...
Scancell Holdings Plc
(`Scancell' or the `Company')
Scancell develops new vaccine for the treatment of lung cancer
Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer
vaccines, announces that a treatment utilising a DNA vaccine based on its
ImmunoBody® technology, in combination with Homspera®, an adjuvant developed by
ImmuneRegen BioSciences, Inc.® has produced encouraging anti-tumour results in
animal models.
The vaccine, known as SCIB2, stimulates immune responses to the lung cancer
antigen NY-ESO-1 and may also have potential utility in oesophageal, liver,
gastric, prostate, ovarian and bladder cancers. Unlike classical adjuvants,
Homspera® did not enhance the SCIB2 systemic immune response but did make it
more effective at the tumour site. This could have profound implications for
cancer vaccine therapy
Scancell is currently conducting a Phase I clinical trial utilising its SCIB1
vaccine which is being developed for the treatment of melanoma. SCIB1 is a
novel DNA vaccine which is also being developed using Scancell's patented
ImmunoBody® technology. ImmunoBody® vaccines generate the high-avidity T-cells
that kill cancer cells.
ImmuneRegen's Homspera® has previously been found to synergise with SCIB1 in an
animal model. Additionally, previous studies have demonstrated efficacy of
Homspera® in enhancing immune responses to infectious disease vaccines, such as
influenza.
Professor Lindy Durrant, Chief Executive Officer of Scancell, commented:
"These are outstanding results for Scancell and a significant milestone for the
Company. The successful application of Scancell's ImmunoBody® technology, in
conjunction with Homspera®, provides further evidence that our ImmunoBody®
vaccine has the potentially groundbreaking ability to augment the immune
responses necessary to destroy cancer. We are delighted to be combining our
efforts with ImmuneRegen and look forward to progressing our work further at
this pivotal moment for Scancell. Shareholders will be kept fully updated with
this significant breakthrough. In addition to this highly positive news, we
have a number of other promising vaccine candidates in development, which we
hope will be the subject of further announcements in due course".
Hal Siegel Ph.D., Chief Scientific Officer of ImmuneRegen, commented:
"We are very pleased with our ongoing collaboration with Scancell and the
results of their studies with Homspera® in conjunction with their ImmunoBody®
technology. This is further evidence of the immunostimulatory activity of our
compound, and also demonstrates a broader anti-tumour effect than previously
reported. Furthermore, these recent studies suggest a specificity regarding the
dendritic cell activity of Homspera that is both intriguing and promising. We
are anticipating additional studies at Scancell will provide further insights
into the activity and value of Homspera as an ImmunoBody® vaccine adjuvant for
a potentially broad spectrum of therapeutic cancer treatments."
ImmuneRegen BioSciences, Inc.® is a wholly owned subsidiary of IR BioSciences
Holdings, Inc. (OTC BB:IRBS.OB)
For further information contact:
Scancell Holdings Plc + 44 (0)207 245 1100
Professor Lindy Durrant
Hansard Communications + 44 (0)207 245 1100
Adam Reynolds/Guy McDougall
Zeus Capital - Nominated Adviser + 44 (0)161 831 1512
Ross Andrews/Tom Rowley
XCAP Securities Plc - Broker +44 (0)207 101 7070
John Belliss/Parimal Kumar
About Scancell
Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1, which entered clinical trials
in 2010, is being developed for the treatment of melanoma.
Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.
A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.
An ImmunoBody® is a human antibody or fusion protein engineered to express
helper cell and CTL epitopes from tumour antigens over-expressed by cancer
cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour
antigens as they have long half-lives and can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of both helper and
CTL responses.
The Immunobody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.